Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024?
We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at ...
Exelixis initiated at buy by Brookline Capital
Brookline Capital Markets initiated coverage of Exelixis (EXEL) with a buy rating, highlighting the company's revenue ...
Hosted on MSN5d
Brookline Capital Initiates Coverage of Exelixis (EXEL) with Buy Recommendation
Fintel reports that on December 23, 2024, Brookline Capital initiated coverage of Exelixis (NasdaqGS:EXEL) with a Buy ...
Principal Financial Group Inc. Decreases Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Principal Financial Group Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.6% during the third ...
Exelixis (NASDAQ:EXEL) Now Covered by Brookline Capital Management
Investment analysts at Brookline Capital Management assumed coverage on shares of Exelixis (NASDAQ:EXEL – Get Free Report) in ...
Exelixis initiated with a Buy at Brookline
Brookline initiated coverage of Exelixis (EXEL) with a Buy rating.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top ...
Brookline starts Exelixis with Buy on commercial drugs, pipeline
Brookline analyst Leah Rush Cann initiated coverage of Exelixis (EXEL) with a Buy rating. The firm anticipates Exelixis will continue to ...
Seeking Alpha4d
Exelixis initiated at buy by Brookline Capital
Brookline Capital Markets initiated coverage of Exelixis (NASDAQ:EXEL) with a buy rating, highlighting the company's revenue potential. The investment firm said it sees Exelixis's (NASDAQ ...
Pharmaceutical Technology3d
Zanzalintinib fumarate by Exelixis for Hypopharyngeal Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Hypopharyngeal Cancer.